Repligen (RGEN) Stock Price, News & Analysis

Company Overview

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to develop and produce biologic drugs. Its products are designed to support key stages of biomanufacturing, including upstream processing, downstream purification, filtration, and process monitoring.

The company’s portfolio includes chromatography products, filtration and single-use systems, process analytics technologies, and recombinant proteins such as Protein A-based products. Repligen’s solutions are used in the production of monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies, and other biological medicines.

Founded in 1981, Repligen is headquartered in Waltham, Massachusetts, and serves biopharmaceutical customers in North America, Europe, Asia, and other international markets. The company operates as a supplier to pharmaceutical and biotechnology manufacturers, as well as contract development and manufacturing organizations. Tony Hunt serves as Repligen’s president and chief executive officer.

Key Stats

• Today's Range: $183.75 to $192.49
• 50-Day Range: $131.06 to $186.75
• 52-Week Range: $100.99 to $192.49
• Volume: 1.06 million shs
• Average Volume: 1.02 million shs
• Market Capitalization: $10.82 billion
• P/E Ratio: 261.36
• Dividend Yield: N/A
• Price Target: $168.57
• Consensus Rating: Buy

Repligen Stock Analysis - MarketRank™

Repligen scored higher than 47% of companies evaluated by MarketBeat, and ranked 542nd out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Repligen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 12 buy ratings, 3 hold ratings, and no sell ratings.

Downside Risk

Repligen has a consensus price target of $168.57, representing about 10.7% downside from its current price of $188.75.

Amount of Analyst Coverage

Repligen has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 26.70%

Earnings Growth

Earnings for Repligen are expected to grow by 26.70% in the coming year, from $2.06 to $2.61 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Repligen is 258.59, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.90.

Price to Earnings Ratio vs. Sector

The P/E ratio of Repligen is 258.59, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.19.

Price to Earnings Growth Ratio

Repligen has a PEG Ratio of 3.41. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Repligen has a P/B Ratio of 5.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.79% of the float of Repligen has been sold short.

Short Interest Ratio / Days to Cover

Repligen has a short interest ratio ("days to cover") of 6.68.

Change versus previous month

Short interest in Repligen has recently increased by 8.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Repligen does not currently pay a dividend.

Dividend Growth

Repligen does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.59

News Sentiment

Repligen has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Repligen this week, compared to 5 articles on an average week.

Search Interest

13 people have searched for RGEN on MarketBeat in the last 30 days. This is an increase of 86% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Repligen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $106,285.00 in company stock.

Percentage Held by Insiders

0.60% of the stock of Repligen is held by insiders.

Percentage Held by Institutions

97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/28/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:RGEN
• CIK: 730272
• Web: www.repligen.com
• Phone: (781) 449-9560
• Fax: 781-250-0115
• Employees: 2,000
• Year Founded: 1981

Price Target and Rating

• Average Price Target for Repligen: $168.57
• High Price Target: $225.00
• Low Price Target: $142.00
• Potential Upside/Downside: -11.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.73
• Trailing P/E Ratio: 259.84
• Forward P/E Ratio: 92.18
• P/E Growth: 3.41
• Net Income: $48.89 million
• Net Margins: 5.29%
• Pretax Margin: 6.64%
• Return on Equity: 5.30%
• Return on Assets: 3.79%

Debt

• Debt-to-Equity Ratio: 0.26
• Current Ratio: 9.05
• Quick Ratio: 7.64

Sales & Book Value

• Annual Sales: $785.10 million
• Price / Sales: 13.65
• Cash Flow: $3.47 per share
• Price / Cash Flow: 54.66
• Book Value: $37.42 per share
• Price / Book: 5.07

Miscellaneous

• Outstanding Shares: 56,436,000
• Free Float: 56,097,000
• Market Cap: $10.72 billion
• Optionable: Optionable
• Beta: 1.05